Cargando…
Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes
Approximately 90% of patients with myelodysplastic syndromes (MDSs) have somatic mutations that are known or suspected to be oncogenic in the malignant cells. The genetic risk stratification of MDSs has evolved substantially with the introduction of the clinical molecular international prognostic sc...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432617/ https://www.ncbi.nlm.nih.gov/pubmed/37267435 http://dx.doi.org/10.1182/bloodadvances.2023010098 |